IGLANBA Trademark

Trademark Overview

On Thursday, February 12, 2026, a trademark application was filed for IGLANBA with the United States Patent and Trademark Office. The USPTO has given the IGLANBA trademark a serial number of 99649970. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, February 12, 2026. This trademark is owned by Emerge Bioscience Pte. Ltd.. The IGLANBA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals; pharmaceutical preparations; pharmaceutical products; insulin; insulin glargine; insulin analog; anti-diabetics; pharmaceuticals for treating diabetes; pharmaceutical preparations for treating diabetes; pharmaceutical products for treating diabetes; pharmaceutical preparations, namely, injectable insulin; pharmaceutical preparations, namely, injectable insulin glargine; pharmaceutical preparations, namely, injectable insulin analog; pharmaceutical preparations, namely, injectable anti-diabetics; injectable pharmaceutical preparations for treating diabetes; injectable pharmaceutical products for treating diabetes; injectors sold filled with insulin; insulin injectors sold filled with insulin glargine; insulin injectors sold filled with insulin analog; injectors sold filled with pharmaceuticals for treating diabetes; injectors sold filled with anti-diabetics
iglanba

General Information

Serial Number99649970
Word MarkIGLANBA
Filing DateThursday, February 12, 2026
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateThursday, February 12, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceuticals; pharmaceutical preparations; pharmaceutical products; insulin; insulin glargine; insulin analog; anti-diabetics; pharmaceuticals for treating diabetes; pharmaceutical preparations for treating diabetes; pharmaceutical products for treating diabetes; pharmaceutical preparations, namely, injectable insulin; pharmaceutical preparations, namely, injectable insulin glargine; pharmaceutical preparations, namely, injectable insulin analog; pharmaceutical preparations, namely, injectable anti-diabetics; injectable pharmaceutical preparations for treating diabetes; injectable pharmaceutical products for treating diabetes; injectors sold filled with insulin; insulin injectors sold filled with insulin glargine; insulin injectors sold filled with insulin analog; injectors sold filled with pharmaceuticals for treating diabetes; injectors sold filled with anti-diabetics

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, February 12, 2026
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEmerge Bioscience Pte. Ltd.
Party Type10 - Original Applicant
Legal Entity Type24 - NOT AVAILABLE
AddressSingapore 069535
SG

Trademark Events

Event DateEvent Description
Thursday, February 12, 2026NEW APPLICATION ENTERED
Thursday, February 12, 2026APPLICATION FILING RECEIPT MAILED

Related Keywords

iglanba insulin pharmaceutical preparations diabetes treating injectable sold injectors filled namely